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<AB>Abstract:   
This document represents the American Society of Parenteral and Enteral Nutrition (ASPEN) 
clinical guidelines to describe best practices in the selection and care of central venous 
access devices (CVADs) for the infusion of home parenteral nutrition (HPN) admixtures in 
adult patients. The guidelines targeted adults >18 years of age in which the intervention or 
exposure had to include HPN that was administered via a CVAD. Case studies, non-English 
studies, or studies of CVAD no longer available in the United States were excluded. In total, 
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564 abstract citations, 350 from Medline and 214 from PubMed/non-MEDLINE databases, 
were scanned for relevance. Of the 564 citations, 13 studies addressed at least 1 of the 6 
guideline-related questions, and none of the studies were prospective and randomized. The 
Grading of Recommendations, Assessment, Development and Evaluation (GRADE) criteria 
were used to adjust the evidence grade based on assessment of the quality of study design 
and execution. Recommendations for the CVAD type, composition, or number of lumens to 
minimize infectious or mechanical complications are based on a limited number of studies 
and expert opinion of the authors, all very experienced in home infusion therapy. No studies 
were found that compared best solutions for routine flushing of lumens (eg, heparin versus 
saline) or for maintaining catheters in situ while treating CVAD mechanical or infectious 
complications. It is clear that studies to answer these questions are very limited, and further 
research is needed. These clinical guidelines were approved by the ASPEN Board of 
Directors. (JPEN J Parenter Enteral Nutr. 2018;XX:xxx-xxx) 
<KW>Keywords 
adults; antibiotic locks; catheter flushing; catheter related blood stream infection; catheter 
salvage; central line associated blood stream infection (CLABSI); central venous access 
device; central venous access device lumens; central venous access device types; central 
venous access material; ethanol locks; guidelines; home parenteral nutrition 
 
 
<H1>PRELIMINARY REMARKS (INTENT OF GUIDELINES) 
This document represents the American Society of Parenteral and Enteral Nutrition (ASPEN) 
Clinical Guidelines to describe best practices in the selection and care of central venous 
access devices (CVADs) for the infusion of home parenteral nutrition (HPN) solutions in the 
adult patient. The mission of ASPEN is to improve patient care by advancing the science 
and practice of clinical nutrition and metabolism.  
 <H2>Guideline Limitations: These ASPEN Clinical Guidelines are based on general 
consensus among a group of professionals who, in developing such guidelines, have 
examined the available literature on the subject and balanced potential benefits of nutrition 
practices against risks inherent with such therapy. These practice guidelines are not 
intended as absolute policy statements. Use of these practice guidelines does not in any 
way guarantee any specific benefit in outcome or survival. The professional judgment of the 
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attending health professional is the primary component of quality medical care delivery. 
Since guidelines cannot account for every variation in circumstances, practitioners must 
always exercise professional judgment when applying these recommendations for individual 
patients. These Clinical Guidelines are intended to supplement, but not replace, professional 
training and judgment. 
 
The guidelines reflect an exhaustive search of the research literature for evidence 
about the best practices related to CVADs used in the care of adult HPN patients. Many of 
the reports excluded from analyses were anecdotal, describing diverse experiences of 
heterogeneous groups of HPN patients without data to address the guideline questions. 
Studies addressing the guideline questions were analyzed and used to develop 
recommendations. Recommendations reflect a review and analysis of the current literature 
and a blend of expert opinion and clinical practicality. The population of adult home patients 
receiving parenteral nutrition (PN) is not homogeneous. These guidelines represent a review 
of published research through September 9, 2017, about the selection and care of CVADs. 
All of the reviewed studies were observational; no prospective randomized clinical trials were 
found that addressed questions about CVADs used for HPN. 
 
A comprehensive search of the medical literature yielded 13 prospective or 
retrospective cohort studies that provided data about CVADs used for HPN administration in 
adults. Study quality and data were critically reviewed by a group of multidisciplinary experts 
in clinical nutrition composed of nurses, dietitians, and a biostatistician. These individuals 
used the Grading of Recommendations, Assessment, Development and Evaluation 
(GRADE) methodology to develop consensus-derived recommendations.1  
 
<H1>Methods 
The GRADE process was used to develop key questions and plan data acquisition and 
conflation for these guidelines.1 The task force of experts began by defining language used 
for the routine care and complications associated with CVADs and keywords to be used for 
the literature search. This was followed by: 1) development of the key questions that were 
the focus of this clinical guideline; 2) establishing a time frame that would be used for the 
literature search; 3) determining the target population (inclusion and exclusion criteria); and 
4) establishing the specific outcomes that would be addressed. Ultimately, 6 questions were 
developed by the guideline experts and approved by the ASPEN Board of Directors. These 
questions and their recommendations are summarized in Table 1. 
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All included studies were prospective or retrospective investigations of clinical 
outcomes tailored to address specific questions. The GRADE criteria were used to adjust the 
evidence based on assessment of the quality of study design and execution. The GRADE 
approach separates the evidence compiled from the recommendation statements, enabling 
independent assessment of the weight of the risks versus (vs) the benefits that occur from 
adopting the recommendation. All recommendations that were based solely on expert 
opinion were deemed as very low. Table 2 describes the standard language and rationale for 
the grade assigned to a recommendation. 
The Centers for Disease Control (CDC) and the Infusion Nurses Society (INS) have 
guidelines and standards that include the insertion, maintenance, care, and surveillance 
monitoring for CVAD complications 
(https://www.cdc.gov/infectioncontrol/guidelines/bsi/updates.html). Their recommendations 
are based on the strength of the study design. They include information regarding some of 
the questions that were identified in these guidelines. However, the majority of their focus is 
based heavily on the acute care setting rather than care in the home. Establishing guidelines 
for use in the home creates unique challenges as care is provided by patients and 
caregivers with little or no medical background, and the environment, supplies, equipment, 
and reimbursement are different compared with hospital settings. 
<H2>Definition 
Home nutrition support therapy refers specifically to the provision of parenteral PN through a 
CVAD in a homecare setting.  
<H2>Target Patient Population for Guidelines 
The target of these guidelines is to determine the type of CVAD that is associated with the 
lowest occurrence of infectious and mechanical complications in adult (>18 years of age) 
patients receiving HPN. Studies that evaluated pediatric HPN and inpatient PN populations 
were excluded. These guidelines are directed toward generalized outpatient populations but, 
like any other management strategy, the infusion therapy selected should be tailored to the 
individual patient.  
<H2>Target Audience 
These guidelines are intended for use by all healthcare providers involved in nutrition 
support of the home patient receiving PN, primarily physicians, nurses, dietitians, and 
pharmacists. These guidelines may also be helpful to patients and their caregivers to assist 
them in the selection of a CVAD. 
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<H1>Literature Search Methodology 
The PubMed/MEDLINE databases were searched through September 9, 2017, for relevant 
citations. To be included in our search results, citations had to be indexed in the “Catheters” 
and “Humans” MeSH folders as well as either the "Parenteral Nutrition, Home" or “Home 
infusion therapy” MesH folders. Then, the non-MEDLINE PubMed database was searched 
for any citation containing at least 1 text-based term from each of the following 2 groups of 
terms. Group 1: “Parenteral,” “HPN,” “TPN,” “Home PN,” “Home Health Care,” “HHC,” “home 
infusion.” Group 2: “catheter,” “Hickman,” “port,” “pic,” “PICC,” “tunnel,” “lock,” “vascular 
access device,” “flush.” Finally, to capture citations which may have been miscataloged by 
MEDLINE indexers, this same text-based strategy was restricted to terms found in the title or 
abstract of the citation and to the publication types “observational study,” “clinical trial,” 
“meta-analysis,” and “validation study” and used to re-search the MEDLINE database.  
<H1>Results 
 In total, this search strategy yielded 564 citations. The MEDLINE database accounted for 
350 citations, and the PubMed/non-MEDLINE database accounted for 214. The abstract for 
each citation abstract was reviewed to determine if it was 1) a randomized clinical trial, meta-
analysis, or cohort study, 2) conducted in adults (>18 years), and 3) an intervention or 
exposure studied that included HPN. Studies meeting these 3 criteria were downloaded for 
further investigation to determine if they contained data that could answer 1 or more of the 6 
specific questions that are addressed in these guidelines. Relevant outcome data included 
the type of catheter material, lumen number and type (tunneled, implanted, or peripherally 
inserted central catheter [PICC]) as they related to infection and mechanical complications, 
flush solutions used for maintenance (eg, heparin, saline), and the impact of antimicrobial 
and/or ethanol locks as a method for salvaging infected CVADs. If these criteria were met, 
the data were abstracted from the article, analyzed, and included in the guidelines. Articles 
were excluded if they did not meet inclusion criteria or contain data that would address at 
least 1 of the 6 guideline questions. 
 <H1>Introduction 
HPN therapy requires patients to have a CVAD. Data obtained from ASPEN’s National 
Patient Registry for Nutrition Care (Sustain) found the duration of HPN therapy varies from 3 
months–34 years for adults.2 The appropriate CVAD that will accommodate these variable 
time intervals is essential to minimize complications and frequent access changes. 
Additionally, prior to selection of the CVAD, the contents of the HPN solution and patient and 
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caregiver preference as well as the ability to care for and monitor for complications all need 
to be considered. The CVADs used for HPN infusion include implanted infusion venous 
access devices (VADs), PICCs, and tunneled catheters,3 each with unique risks (Table 3). 
The most common complications for HPN therapy are CVAD mechanical complications and 
central line–associated blood stream infections (CLABSIs). During the early years of HPN, 
removal of the CVAD was advocated for mechanical problems, such as clotting due to 
improper flushing when patency could not be resolved as well as for CLABSI. Treatment 
following CVAD removal for CLABSI was typically followed by the administration of several 
days of intravenous antibiotics. Re-insertion of the CVAD was only considered once the 
infection was resolved.  
The expansive duration of HPN (ranging from months–decades) has shifted the 
focus of care to salvaging rather than removing the CVAD. Salvaging a long-term catheter is 
defined as trying to save or keep the catheter in place while treating mechanical or infectious 
complications. These can range from mechanical repair of a broken tunneled catheter to a 
full course of IV antibiotics to treat a catheter infection. This salvaging is beneficial to the 
patient as every CVAD insertion limits the number of remaining viable veins that can be used 
to reinsert a new CVAD in the future. Infusion of concentrated antibiotics sensitive to the 
offending organisms into the CVAD lumen was one of the first alternatives used to avoid 
venous access removal. To limit risks of antibiotic resistance and systemic toxic effects, the 
CDC Catheter Guidelines recommend prophylactic antibiotic lock solutions only in patients 
with long-term CVADs who have a history of multiple CLABSIs despite optimal maximum 
adherence to aseptic technique.4 However, antibiotics may not adequately infiltrate the 
biofilm, a substance that allows microbial colonization along CVAD surfaces when in situ. 
This led to the treatment of CLABSI with concentrated ethanol as it has the ability to 
penetrate the biofilm and is bactericidal as well as fungicidal.5 These properties have led 
many clinicians to use ethanol for treatment as well as prophylaxis in HPN populations.  
The goals of HPN care are to 1) teach patients to become independent in their care, 
2) keep patients in their home, and 3) maintain their quality of life by avoiding 
hospitalizations or unnecessary resource utilization needed to treat CVAD complications. To 
achieve these goals, clinicians must be knowledgeable in regard to the best CVAD on the 
market and the most effective treatment options that minimize risk of mechanical or 
infectious complications. Therefore, the recommendations provided in this guideline are 
tailored to address these issues and provide a science-based starting point for individualized 
HPN therapy.  
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Question 1: Does the type of CVAD (tunneled, implanted, or PICC) influence CLABSI 
rates? (See Table 4.)  
Recommendations 1. Based on observational studies and expert consensus, we suggest 
tunneled CVADs should be selected for adult patients anticipated to require long-term daily 
PN infusions. If the duration of HPN is uncertain or of short duration (ie, <31 days), PICCs 
may be used.6  
Quality of Evidence: Low  
GRADE Recommendation: Weak 
Rationale 1: No randomized controlled trials were found that addressed this question. Nine 
observational studies were found that compared CLABSI and types of CVAD.7-13 An 
observational study of severely ill cancer patients compared CLABSI rates in tunneled, 
implanted, or PICC VADs, and found no significant difference between the groups even 
though implanted ports had a longer dwell time.7 Severity of illness was not controlled for 
and may have been a factor contributing to the non-significant differences among the 
catheter groups.  
Four studies compared CLABSI rates in patients with tunneled vs implanted CVADs 
(not PICC).8-10,12 Three reported significantly higher rates of infections in patients with 
implanted CVADs.8-10 Two of these studies8,9 noted a higher proportion of cancer patients 
with implanted catheters compared with tunneled catheters, suggesting the higher infection 
rates observed may be due to the underlying disease, immunosuppression, and/or the use 
of implanted CVADs. Buchman et al10 found higher rates of infections for implanted CVADs 
in a cohort of patients that predominantly had intestinal failure as their primary diagnosis 
rather than cancer. In a small case-series study of 6 severely ill cancer patients that first 
received a tunneled CVAD followed by an implanted CVAD, a higher rate of infection was 
reported in patients with tunneled CVADs.12 Due to the very small sample size and sampling 
on the dependent variable, it is difficult to draw any conclusion from this study. 
In addition to Cotogni et al,7 3 other studies compared CLABSI rates in tunneled vs 
PICC CVADs.11,13,14 Christenson and associates and Bech and associates appeared to 
analyze the same dataset of Danish HPN patients, and while different questions were asked, 
similar results were found. Christensen et al14 reported higher CLABSI rates for PICC 
compared with tunneled CVADs and a shorter time to first infection (84 ± 94 days vs 297 ± 
387 days; P < .05). After controlling for environmental factors, Bech et al11 reported identical 
time to first infection (83.91 ± 93.8 vs 297.2 ± 386.9 days; P <. 001) that was more 
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significant. Toure and associates13 found higher rates of infections for the tunneled vs PICC 
CVADs; however, shorter median time to first infection occurred in the PICC group (60 vs 
134 days; P = .008). Patients in the tunneled group received HPN prior to entry in the study; 
thus, this “greater unaccounted for exposure time” likely biased these results. Additionally, 
almost a third of patients in both groups were receiving taurolidine citrate locks, suggesting 
some or all were at higher risk of infection.  
Ross et al15 described CLABSI rates in 1046 HPN patients from a national cohort of 
patients in the United States of which 13.2% were <18 years of age. They found patients 
with tunneled or implanted CVADs experienced higher infection rates (0.51 and 0.66/total 
PN days, respectively) than those with PICCs (0.41/total PN days). Children experienced a 
higher rate of infection compared with adults; however, their reported infection rates by 
catheter type include both children and adults, which precluded inclusion of this study in our 
analyses.  
In summary, 8 studies comparing different CVAD types found lower infection rates in 
patients with tunneled CVADs compared with implanted or PICC CVADs, and when 
reported, longer time to first infection suggesting tunneled CVADs may be preferable for 
patients expected to require HPN over a long period of time. Only 1 study that included both 
adults and pediatric patients found PICCs to experience lower rates. The impact of the 
concomitant use of implanted CVADs used for HPN and chemotherapy remains unknown. 
Question 2. Does the number of CVAD lumens influence CLABSI rates? (See Table 5.) 
Recommendation 2. Based on 1 observational study and expert opinion, we suggest using 
the fewest number of lumens required for individual patient therapy.  
Quality of Evidence: Very Low  
GRADE Recommendation: Weak 
Rationale 2: Both the CDC and INS recommend selection of CVADs with the fewest number 
of lumens. In our more narrow search of adult HPN patients, we found 1 retrospective 
observational study comparing the number of CVAD lumens for risk of CLABSI.10 This study 
compared infection rates in HPN patients from 1 homecare provider in patients with single-
lumen, double-lumen, and triple-lumen tunneled CVADs. Significantly lower CLABSI rates 
occurred in patients with a single-lumen CVAD, followed by the double lumen. Triple-lumen 
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CVADs had the highest CLABSI rate (0.31 vs 0.7 vs 0.87/1,000 CVAD days, respectively; P 
= .001).  
In summary, insertion of a CVAD with the fewest number of lumens to accommodate 
the patient’s clinical status reduces the number of manipulations required for flushing pre-
HPN and post-HPN and medication administration. CVADs with fewer lumens reduce the 
number of opportunities for contamination, are more economical, and require less 
maintenance for patients and caregivers. Further, it is highly unlikely restricting the catheter 
to the fewest lumens needed to provide care will result in any increase in harm.  
Question 3. Does the type of CVAD material influence CLABSI rates? (See Table 6.) 
Recommendation 3. We cannot make a recommendation at this time regarding CVAD 
composition to minimize infection.  
Quality of Evidence: Very Low  
GRADE Recommendation: Further research is needed 
Rationale 3: Per the information presented in the CDC guidelines, due to their surface 
irregularities, the type of VAD material plays an important role in the development of 
CLABSI. These irregularities are thought to heighten the ability of microorganisms to adhere 
and attach to the surface. VADs manufactured with silicone have been shown to have higher 
risks of CLABSI compared with polyurethane.16 In our narrower search, including exclusively 
adult HPN patients, only 1 study compared the role of CVAD composition with CLABSI. No 
statistical significance was found in this prospective, non-randomized study of 40 silicone 
and 13 polyurethane CVADs in 42 patients.17 Only CVADs manufactured with silicone and 
polyurethane were included in the study. 
To summarize, different CVAD materials may be more susceptible to the 
development of fibrin sheaths and biofilms that form within the CVAD lumen and the CVAD 
itself. Tunneled and implanted ports are made of silicone, which may lend itself to increase 
infection rates compared with PICCS manufactured with polyurethane.  
Question # 4: What is the best CVAD for minimizing mechanical complications? (See 
Table 7.) 
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Recommendation 4: Based upon 6 observational cohort studies,7,9,12-14,17 the risk for 
mechanical complications does not differ by the type of CVAD. Therefore, the choice of 
CVAD should be selected based upon length of therapy, patient choice, and the ability of the 
patient/caregiver to care for the CVAD.  
Quality of Evidence: Low 
GRADE Recommendation: Low 
Rationale 4: A number of factors related to the CVAD type, size, material, and placement 
technique are hypothesized to contribute to mechanical complications of CVADs in patients 
receiving HPN; however, investigations in this area are limited. 
When comparing polyurethane vs silicone CVADs, Beau and colleagues17 found no 
significant difference in catheter CVAD obstruction or thrombosis among patients with short 
bowel syndrome (SBS). Additionally, Toure et al13 found no significant difference in the 
incidence of non-infectious CVAD complications/1000 patient days in patients with SBS or 
Crohn’s disease receiving HPN via a PICC or tunneled CVAD. The first complication 
occurred later in patients with a tunneled CVAD; however, this difference was not significant 
(180.2 ± 154.7 days vs 118.1 ± 129.3 days; P = .09).  
Guglielmi et al9 compared the differences of HPN complications in 270 patients with 
and without cancer. Cancer patients received HPN via implanted ports; HPN was delivered 
via tunneled CVADs in the non-cancer participants. No significant difference in incidence 
rates of mechanical complications occurred between these groups (0.28 vs 0.91/1000 CVAD 
days; not significant). Christensen et al14 also evaluated mechanical complications in 
intestinal failure (IF) patients requiring HPN through a PICC or tunneled CVAD. 
Unfortunately, the material, brand, and size of the PICCs used did not remain constant 
during the study (silicone 4F Groshong PICC vs 5F polyurethane PICC), limiting 
interpretation of the findings. Patients with type II IF more often received a PICC, whereas 
long-term HPN patients with type III IF received tunneled CVADs. The authors defined type 
II IF as patients who had a prolonged acute condition, metabolically unstable, requiring 
intravenous therapy over a limited period of time, and type II patients were those with a 
chronic condition, metabolically stable requiring PN over months to years. Mechanical 
complications leading to CVAD removal was significantly higher in the PICC group (0.60 vs 
1.5; P = .0011).  
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Cotogni and colleagues7 prospectively observed CVAD complications in cancer 
patients with 4 types of VADs (PICC, Hohn PICC, tunneled, and implanted ports). 
Mechanical complications were 0.8/1000 catheter days. The Hohn CVAD experienced a 
significantly higher rate of catheter dislocation than the tunneled or PICC. The Hohn catheter 
is infrequently used in HPN patients in the United States.  
In summary, based on these 6 studies when mechanical complications did occur, it 
appears to be due to CVAD design. PICCs, without an internal anchoring design, such as 
the cuff found on tunneled catheters, may be at increased risk for dislodgement. Additionally, 
PICCs that are not sutured in place, often exit on the distal arm, and require dressing 
changes that are difficult to perform independently (compared with a tunneled catheter 
exiting the chest) may also lend themselves to be accidently becoming dislodged. Tunneled 
VADs would have increased rates of malfunction compared with implanted ports due to 
cracking of the VAD hub and weakening of the lumen from repeated VAD clamping during 
and after flushing.  
Question 5: Should antimicrobial or ethanol locks be used vs standard care for 
treating or preventing CVAD infections? (See Table 8.) 
Recommendation 5: Based upon 2 studies, ethanol and antimicrobial lock instillations 
should be considered when used to prevent recurrent infection. Tunneled CVADs instilled 
with concentrated vancomycin demonstrated a decrease in CLABSI in 1 study. One study 
showed that there was no difference in removing an infected CVAD vs using a concentrated 
antibiotic lock followed by ethanol locks for several days.  
Quality of Evidence: Low  
GRADE Recommendation: Weak  
Rationale 5. The CDC recommends that prophylactic antimicrobial locks be used only for 
long-term VADs with repeated CLABSIs following an in-depth review to insure that aseptic 
techniques are being followed and adhered to. In this narrower literature search of adult 
HPN patients, no randomized trials in adult HPN patients assessed the impact of 
antimicrobial or ethanol locks to treat or use prophylactically to prevent CLABSI. Three 
observational studies explored this question.18-20  Lawinski et al20 retrospectively compared 
differences in outcome in HPN patients (N = 428) with CVAD removal vs those treated first 
with ethanol locks followed by antibiotic lock therapy. Of the 331 episodes of CLABSI, the 
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majority (231 of the CVADs) were automatically removed for specific criteria (eg, 
colonization with fungi or specific bacterial strain which were resistant to most antimicrobials, 
etc) without using a lock therapy. Of the 100 CVADs that remained in situ, a 95% ethanol 
solution was instilled daily for 4 days, followed by an antibiotic lock solution which was 
selected based upon the patient’s blood culture results. There were no differences in the 
recurrence of CLABSIs with the same organism between the 2 groups over a period of 120 
days.  
The use of a prophylaxis lock of either a highly concentrated antibiotic or a 70% 
ethanol solution was studied in 59 patients who experienced a total of 313 CLABSI 
episodes: 264 before and 49 following initiation of the lock solution.19 There were statistically 
significant differences in the prelocking groups (10.97 + 25.92 infections/1,000 CVAD days) 
and postlocking groups (1.09 + 2.53 infections/1000 CVAD days) as well as for the CVADs 
that instilled vancomycin (11.59 days prelocking and 1.04 days postlocking/1000 CVAD 
days; P < .001). 
  John et al18 also examined the impact of CLABSI-related hospital admission using a 
70% ethanol lock solution in adult HPN patients before and after ethanol lock using a quasi-
crossover study design. Overall, 31 patients experienced 273 CLABSI-related admissions 
prior to ethanol lock treatment (10.04/1000 CVAD days) compared with 47 CLABSI after 
ethanol lock (6.48/1000 CVAD days; P = .005). When data were adjusted to include only 
tunneled CVADs, a significant decrease in CLABSI from 10.1 to 2.9/1000 VAD days before 
and after ethanol lock use remained.  
In summary, while few studies have demonstrated the benefits of ethanol and 
antimicrobial locks in the adult population, a larger body of research exists for the pediatric 
HPN population. This research has consistently reported decreased rates of CLABSI.21-23 
However, increased VAD breakage and thrombosis rates with the use of ethanol have also 
been cited with the use of silicone CVADs.23-25 It should be noted that ethanol locks can only 
be used if the CVAD material is silicone because a 70% ethanol lock solution has the 
potential to weaken CVADs constructed of polyurethane.26 The effect of different dwell times 
and frequency, as well as concentrations of ethanol, on VAD integrity all are areas that 
require further investigation. Antimicrobial lock solutions also present difficulties due to the 
potential to develop antimicrobial resistance as well as risks due to side effects and allergic 
reactions. Additionally, studies investigating antimicrobial locks differ on the medication 
used, dose, and CVAD dwell times.  
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Question #6: Should saline or heparin locks be used for CVAD maintenance?  
Recommendation 6. No recommendations can be made as to which flush solution should 
be used to maintain patency for HPN CVADs due to the lack of studies.  
Quality of Evidence: Very Low 
GRADE Recommendation: Expert opinion 
Rationale 6: No studies have examined the impact of flushing with normal saline vs 
heparinized saline to reduce intraluminal clotting for adult patients infusing HPN. 
Manufacturer guidelines are generally followed regarding the use and frequency of heparin 
flush in open-ended CVADs. For valved or closed-tip CVADs, manufacturers recommend 
normal saline flushes. Home infusion providers most often follow standards of practice 
developed by the Intravenous Nurses Society who recommend flushing CVADs before and 
after medication administration with preservative-free 0.9% sodium chloride, followed by 
either heparin 10 U/mL or preservative-free 0.9% sodium chloride. Manufacturer guidelines 
and the type of needleless connector used also guides the clinician in making an informed 
decision as to flushing. 
Although there are no studies in adult HPN patients that evaluated the efficacy of 
various flush solutions a priori, the prospective study by Lyons et al of 90 homecare patients 
that included 7 HPN patients infusing various therapy types via a PICC were randomized 
into 3 different flushing protocols.27 The flushing protocols compared were saline alone, 
saline with heparin 10 U/mL, and saline with heparin 100 U/mL. Results indicated that the 
saline-only group required additional home RN visits to assess for sluggishness/occlusions 
(32.1% compared with 15.6% for the 100 U/mL and 13.3% for the 10 U/mL; P = .150). This 
group also experienced the highest percentage of patients requiring tissue plasminogen 
activator (tPA) to restore PICC patency (25% vs 9.4% and 10% in the 100 U/mL and 10 
U/mL, respectively; P = .160). Both of these results trended toward significance, likely 
reflecting the small sample sizes. The impact of additional home visits by a registered nurse 
and the use of tPA needs to be considered when evaluating the benefits of the type of 
flushing solution.  
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In summary, there is no strong evidence to support the use of heparin vs saline flush 
solutions to maintain CVAD patency. This challenges the homecare clinician to further study 
the use of saline flush solutions due to the increased cost to provide heparin flushes as well 
as the potential for the development of heparin-induced thrombocytopenia.  
<H1>Summary 
These guidelines are tailored to assist clinicians to use best practices in the selection and 
care of CVADs for the infusion of HPN solutions in the adult patient. Due to the absence of 
randomized control studies, our recommendations to answer these questions are based 
upon observational cohort studies and expert opinion. For all of our questions, the quality of 
evidence was either low or very low. It is our hope that this systematic search strategy, 
followed by meticulous data abstraction, will provide clinicians with the most current scientific 
evidence to integrate with their clinical expertise and enable them to optimize catheter care 
for their HPN patients and to underscore the need for research in the homecare population.  
These recommendations serve only as a beginning point to stimulate interest in 
developing the next generation of studies to provide optimal care to our HPN population. We 
selected key questions, but are aware that these as well as other questions remain 
unanswered. It is clear that further multidisciplinary research is needed to continue the quest 
to decrease or eliminate complications for our HPN patients.  
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Table 1. Guidelines for the Selection and Care of Central Venous Access Devices for Adult 
Home Parenteral Nutrition Administration. 
 
  
Questions and Recommendations Evidence/GRADE 
Q1. Does the type of CVAD (tunneled, implanted, or PICC) influence CLABSI rates? 
R1. Based on observational studies and expert consensus, we suggest tunneled CVADs 
should be selected for adult patients anticipated to require long-term daily PN infusions. 
If the duration of HPN is uncertain or of short duration (<30 days), PICCs may be used. 
Quality of Evidence: low 
 
GRADE: weak 
Q2. Does the number of CVAD lumens impact CLABSI rates? 
R2. Based on 1 observational study and expert opinion, we suggest using the fewest 
number of lumens required for individual patient therapy. 
Quality of Evidence: very low 
 
GRADE: weak 
Q3. Does the type of CVAD material influence CLABSI rates? 
R3. We cannot make a recommendation at this time regarding CVAD composition to 
minimize infection. 
Quality of Evidence: very low 
 
GRADE: further research is 
needed 
Q4. What is the best CVAD for minimizing mechanical complications? 
R4. Based upon observational cohort studies, the risk for mechanical complications 
does not differ by the type of CVAD 
R4. The choice of CVAD should be selected based upon length of therapy, patient 
choice, and the ability of the patient/caregiver to care for the CVAD.  
 
Quality of Evidence: low 
 
GRADE: low 
Q5. Should antimicrobial/ethanol locks be used versus standard care for treating or preventing 
CVAD infections? 
R5. No recommendation can be made at this time. 
Quality of Evidence: low 
 
GRADE: weak 
Q6. Should saline or heparin locks be used for CVAD maintenance? 
R6. No recommendations can be made as to which flush solution should be used to 
Quality of Evidence: very low 
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maintain patency for HPN CVADs due to the lack of studies. GRADE: expert opinion 
CLABSI, central line–associated blood stream infection; CVAD, central venous access 
device; GRADE, Grading of Recommendations, Assessment, Development and Evaluation; 
HPN, home parenteral nutrition; PICC, peripherally inserted central catheter; PN, parenteral 
nutrition. 
 
Table 2: Language for Guidelines Recommendations. 
Quality of 
Evidence 
Weighing Risks 
Versus Benefits 
Grading of 
Recommendations, 
Assessment, 
Development and 
Evaluation 
Recommendations 
Clinical Guideline 
Statement 
High to very low Net benefits 
outweigh harms 
Strong We recommend 
High to very low Tradeoffs for 
patient are 
important 
Weak We suggest 
High to very low Uncertain tradeoffs Further research 
needed 
We cannot make a 
recommendation at 
this time. 
 
 
 
Table 3: Types of Central Vascular Access Devices for HPN. 
Type Dwell Time Therapeutic 
Applications 
PN Considerations 
PICCs Maximum dwell 
time is unknown. 
Suitable for acute 
care and short-term 
and medium-term PN 
for adults and 
pediatric patients 
Associated with an 
increased risk for deep 
vein thrombosis, 
limiting use for 
indefinite PN therapy 
and situations where 
vessel preservation is 
a priority. Antecubital 
location of exit site 
hinders self-care and 
activity. Clothing may 
not always cover 
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insertion site, 
potentially having a 
negative impact on 
body image; may be 
easily removed when 
infected or PN is no 
longer needed.  
Tunneled CVADs 
(Hickman, Broviac, 
Hohn types) 
3 months–years Suitable for long-term 
PN; the presence of a 
cuff within the tunnel 
inhibits microbial 
migration and 
decreases risk of 
dislodgement. 
No restrictions on 
upper extremity 
activity; position on 
chest facilitates self-
care; VAD can be 
easily hidden under 
clothing. 
Implanted ports 6 months–years Primarily intended for 
low-frequency, 
intermittent access. 
Associated with 
lowest risk for 
CLABSI due to 
reduced manipulation. 
The presence of an 
indwelling needle to 
continuous or 
frequent access 
offsets the reduced 
infection benefit.  
Suitable for PN in 
selected 
circumstances; 
motivated patients can 
learn access 
procedures; body 
image remains intact; 
requires no local site 
care when device is 
not accessed. PN may 
increase risk for 
CLABSI and occlusion 
in children with 
cancer. 
Adapted with permission from the American Society for Parenteral and Enteral Nutrition.28  
CLABSI, central line–associated blood stream infection; CVAD, central venous access 
device; HPN, home parenteral nutrition; PICC, peripherally inserted central catheter; PN, 
parenteral nutrition; VAD, venous access device.  
 
 
 
Table 4: Question 1: Does the type of CVAD (tunneled, implanted, or PICC) influence CLABSI rates? 
Rules for tables: Within each question, studies are listed in chronologic order with the newest 
studies placed first. When there was >1 study in a given year, studies were placed in alphabetic 
order according to the author’s last name. 
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Reference Study Design Study Aim(s) Population, Setting, N Results/Outcome Comments 
Christensen et al14  Retrospective cohort 
 
Compared 
complication rates of 
tunneled CVADs and 
PICCs in 1 Danish 
Center 
136 adult HPN 
patients 
Total of 295 CVADs; 
169 tunneled CVADs 
and 126 PICCs 
CLABSI 0.57/1000 
catheter days in 
tunneled CVADs group 
compared with 1.63 in 
PICC group (P = .0001) 
Local infection higher 
in PICC group vs 
tunneled CVADs (1.00 
vs 0.24/1,000 CVAD 
days, P = .000) 
Mean time to first 
CLABSI higher in 
tunneled CVADs than 
PICCs (297 ± 387 days 
versus 84 ± 94 days, P 
< .05) 
Unclear if CLABSI was 
defined for tunneled 
CVADs at the time of 
catheter removal or 
symptoms of infection. 
Unclear that when 
tunneled CVADs 
developed infection, 
was the CVAD treated 
in situ. This could have 
resulted in a lower 
than actual infection 
rate. 
PICCs were inserted 
when patient not able 
to care for the CVAD. 
Patients who had an 
acute condition, 
metabolically unstable 
requiring IV 
supplementation over 
limited period of time 
more often received a 
PICC. 
Bech et al11  Retrospective cohort Investigated whether 
environmental risk 
factors influenced the 
time to first CVAD-
related infection 
Adult HPN patients 
Total of 295 CVADs in 
136 patients 
 
Incidence of 
infections/1000 CVAD 
days was significantly 
increased in the PICC 
group (1.43 ± 0.20) 
compared with 0.95 + 
0.390 in the tunneled 
CVAD group  
Mean number of days 
to first infection was 
significantly decreased 
in the PICC group vs in 
the tunneled CVADs 
group (297.21 + 
386.91 vs 83.91 + 
There was no mention 
why 311 patients did 
not meet the inclusion 
criteria. 
The authors reported 
a total of 77 CLABSIs, 
but only 67 were 
included in the 
analysis. 
Patients did not keep a 
log in the home about 
if a homecare nurse or 
the patient preformed 
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93.754, respectively)  
Environmental factors: 
the number of infusion 
days per week, 
colectomy with stoma, 
smoking, if a 
homecare nurse 
managed the CVAD 
care, and an elevated 
C-reactive protein at 
time of insertion was 
not statistically 
significant among the 
2 groups 
Mean CLABSI 
incidence significantly 
increased in the 
tunneled CVADs group 
if the CVAD was 
managed by a 
homecare nurse 
compared with those 
who were not (1.45 + 
0.68 vs 0.56 ± 0.24/ 
1000 CVAD days  
Time to first infection 
decreased CLABSI in 
the PICC group by a 
factor of 2.47 with 1 
additional infusion 
day/week. 
CVAD care. 
 
Toure et al13 Prospective cohort A comparative study 
of peripherally 
inserted and tunneled 
CVAD complications 
196 adult HPN 
patients 
133 tunneled CVADs 
and 71 PICCs 
CLABSI rate for 
tunneled CVADs was 
1.87/1000 CVAD days 
and 1.05 for PICCs  
Median number of 
days to first CVAD 
complication was 134 
(16–674) for tunneled 
CVADs and 60 (25–
Taurolidine-citrate 
locks were used in 
35.4% of the tunneled 
CVADs and 36.62% of 
the PICCs from the day 
of insertion. 
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125) days for PICCs 
Buchman et al10 
 
Retrospective cohort Determined the risk 
factors for CLABSI in 
HPN patients. 
Adult (N = 125) and 
pediatric (N = 18) HPN 
patients 
Total of 331 CVADs; 
268 were tunneled 
and 63 implanted 
ports 
 
CLABSI significantly 
higher in the 
implanted port group 
than in the tunneled 
group (0.66 and 
0.32/1000 CVAD days, 
respectively. 
CLABSI significantly 
higher in adults with a 
triple-lumen CVAD 
(0.87/1000 CVAD days 
for triple lumen; 0.7 
for double lumens and 
0.31 for single lumens) 
Pediatric population 
data was included, but 
the groups were 
compared separately 
and the data were 
separated for adults 
versus children. 
Cotogni et al7 
 
Prospective, 
observational 
Investigated CVAD 
complications in 
cancer patients with 4 
types of VADs (PICC, 
Hohn, tunneled CVAD, 
implanted ports) 
254 adult HPN 
patients 
289 CVADs; 
65 PICCs, 107 Hohns, 
45 tunneled CVADs, 72 
implanted ports 
No statistical 
differences between 
the 4 types of CVADs 
for local infection, 
CLABSI/1000 CVAD 
days or /1000 HPN 
days 
Multivariate analysis 
demonstrated PICC 
CLABSI rate 
significantly lower 
when compared with 
Hohn and tunneled 
CVADs and for 
implanted ports 
compared with Hohn 
and tunneled CVADs 
High mortality rate 
(210 of 289 patients 
died). 
 
Guglielmi et al9 
 
Prospective cohort Described the long-
term HPN frequency 
of complications both 
in adult cancer and 
non-cancer patients 
270 adult HPN 
patients 
139 patients with a 
cancer diagnosis and 
131 without cancer 
Incidence of sepsis in 
cancer patients was 
0.71/1000 CVAD days 
who had implanted 
ports inserted 
compared with 0.46 in 
non-cancer patients 
who had tunneled 
Different CVAD types 
in cancer and non-
cancer patients  
CLABSI not defined 
HPN protocols were 
different between the 
2 groups. Patient 
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CVADs  
Local skin infections 
were 0.03/1000 CVAD 
days in the tunneled 
CVAD non-cancer 
group, and 0.01/1000 
CVAD days in the 
cancer implanted port 
group 
 
training program was 
shortened to 3 days in 
the cancer group 
compared with 7–14 
days; periodic home 
nurse follow-up visits 
were not conducted, 
and the PN solution 
bag was premixed 
compared with a 
personalized mixture. 
Survival curves 
between the 2 groups 
was statistically 
significant.  
No definition given for 
local skin infection or 
if the results were 
reported in CVAD or 
HPN days. 
Santarpia et al8 Retrospective, cohort CLABSI in oncology vs 
non-oncology patients, 
CLABSI by type of 
CVAD (totally 
implanted vs partially 
implanted tunneled 
CVAD) 
Adult HPN patients 
(N = 296) 
156 totally implanted 
ports and 140 partially 
implanted CVADs 
 
Infection rates 
significantly lower in 
partially implanted 
tunneled CVADs 
compared with totally 
implanted ports 
CVAD days not 
available by type of 
CVAD. 
More patients with 
oncology diagnosis 
than non-oncology. 
Gaggioti et al12 
 
Retrospective HPN 
crossover 
Compared implanted 
ports and tunneled 
silicone CVADs 
6 adult HPN patients;  
All 6 previously had a 
silicone tunneled 
CVAD and changed to 
an implanted port 
Tunneled CVAD sepsis 
rate was 3.3/1000 
days compared with 
0.9/1000 CVAD days in 
the implanted port 
Authors did not state 
if the 1000 days were 
CVAD or HPN days. 
No statistics given in 
the paper. 
Small study group. 
CLABSI, central line–associated blood stream infection; CVAD, central venous access 
device; HPN, home parenteral nutrition; IV, intravenous; PICC, peripherally inserted central 
catheter; VAD, venous access device; vs, versus. 
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Table 5. Question #2: Does the number of CVAD lumens impact CLABSI rates? 
 
Reference Study Design Study Aim(s) Population, 
Setting, N 
Results/Outcome Comments 
Buchman et 
al10 
 
Retrospective 
cohort 
Determined 
the risk 
factors for 
CLABSI in 
HPN patients. 
Adult (N = 
125) and 
pediatric (N = 
18) HPN 
patients 
Total of 331 
CVADs; 268 
of which 
were 
tunneled and 
63 implanted 
ports 
 
CLABSI 
significantly higher 
in the implanted 
port group than in 
the tunneled 
group (0.66 and 
0.32/ 1000 CVAD 
days, respectively 
CLABSI 
significantly higher 
in adults with a 
triple-lumen 
CVADs (0.87/1000 
CVAD days; 0.7 for 
double lumens 
and 0.31 for single 
lumens) 
Pediatric 
population 
data was 
included but 
the groups 
were 
compared 
separately 
for adults 
versus 
children. 
CLABSI, central line–associated blood stream infection; CVAD, central venous access 
device; HPN, home parenteral nutrition. 
 
 
 
 
 
Table 6: Question #3: Does the type of CVAD material influence CLABSI rate? 
Reference Study 
Design 
Study Aim(s) Population, 
Setting, N 
Results/Outcome Comments 
Beau et 
al17  
 
Cohort, 
prospective 
Compared 
experience of long-
term complications 
with polyurethane 
Adult HPN 
patients 
N = 53 
CVADs in 42 
There were no 
obstructions 
reported in the 
polyurethane 
Years of 
recruitment 
varied 
between the 
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(LeaderCuff/Vygon) 
and silicone 
(Lifevac/Vygon) 
tunneled, cuffed 
CVADs 
patients group and 
0.05/patient year 
of HPN in the 
silicone group 
Dislodgement and 
thrombosis/patient 
year of HPN not 
statistically 
significant  
Fracture and hub 
dysfunction higher 
in the 
polyurethane 
group (0.5/patient 
year of HPN) than 
the silicone group 
(0.03/patient year 
of HPN) 
2 groups. 
Practice may 
have changed 
between 
1991–1998. 
More patients 
in the silicone 
CVAD group 
(N = 31) as 
well as CVADs 
(N =40) 
compared 
with the 
polyurethane 
group with 11 
patients and 
13 CVADs. 
Measurement 
done per 
patient year 
of HPN. 
CLABSI, central line–associated blood stream infection; CVAD, central venous access 
device; HPN, home parenteral nutrition.
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Table 7: Question #4: What is the best CVAD for minimizing mechanical complications? 
Reference Study Design Study Aim(s) Population, Setting, N Results/Outcome Comments 
Christensen et al14  
 
Retrospective cohort 
 
Compared 
complication rates of 
tunneled CVADs and 
PICCs in 1 Danish 
Center 
136 adult HPN 
patients 
Total of 295 CVADs; 
169 tunneled CVADs 
and 126 PICCs 
 
If removal was due to 
a mechanical cause 
(CVAD fell out, pulled 
out by mistake, 
occlusion, broken or 
other defects) PICC 
removal was higher 
(1.5 compared with 
0.6/1000 CVAD days)  
 
PICCs were inserted 
when patient not able 
to care for the CVAD. 
Patients who had an 
acute condition, 
metabolically unstable 
requiring IV 
supplementation over 
limited period of time 
more often received a 
PICC. 
Toure et al13 Prospective cohort Compared rates of 
complications 
associated with 
peripherally inserted 
and tunneled CVADs 
196 adult HPN 
patients 
133 tunneled CVADs 
and 71 PICCs 
There was no 
difference in non-
infection 
complications 
between PICC and 
tunneled CVADs 
catheters 
The mean number of 
catheter days to non-
infection 
complications was not 
significant between 
the 2 CVAD types 
Non-infectious 
complications defined 
as occlusion, venous 
thrombosis, 
pericarditis, breakage, 
and leakage at the 
VAD site. 
Cotogni et al7 
 
 
Prospective, 
observational 
Investigated CVAD 
complications in 
cancer patients with 4 
types of VADs (PICC, 
Hohn, tunneled 
CVADs, implanted 
ports) 
254 adult HPN 
patients 
289 CVADs;  
65 PICCs, 107 Hohns, 
45 tunneled CVADs, 72 
implanted ports 
There were no 
differences in 
mechanical 
complications/1000 
CVAD days or /1000 
HPN days between the 
4 CVADs 
There were 16 
catheter dislocations 
for the Hohn, 
compared with 4 for 
the tunneled and 5 for 
High mortality rate 
(210 of 289 patients 
died). 
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PICCs  
Guglielmi et al9 
 
Prospective cohort Described the long-
term HPN frequency of 
complications both in 
adult cancer and non-
cancer patients 
270 adult HPN 
patients 
139 patients with a 
cancer diagnosis and 
131 without cancer 
Overall, incidence of 
mechanical 
complications higher 
in the non-cancer 
patients with tunneled 
CVADs compared with 
the cancer patients 
with implanted ports 
(0.91 and 0.82/1000 
patient days, 
respectively)  
Different CVAD types 
in cancer and non-
cancer patients.  
HPN protocols were 
different between the 
2 groups. Patient 
training program was 
shortened to 3 days in 
the cancer group 
compared with 7–14 
days; periodic home 
nurse follow-up visits 
were not conducted. 
Lacking mechanical 
definition. 
Beau et al17  
 
Cohort, prospective Compared experience 
of long-term 
complications with 
polyurethane 
(LeaderCuff/Vygon) 
and silicone 
(Lifevac/Vygon) 
tunneled, cuffed 
CVADs 
Adult HPN patients 
N = 53 CVADs in 42 
patients 
There were no 
obstructions reported 
in the polyurethane 
group and 0.05/ 
patient year of HPN in 
the silicone group 
Dislodgement and 
thrombosis/patient 
year of HPN was not 
statistically significant  
Fracture and hub 
dysfunction were 
higher in the 
polyurethane 
(0.5/patient year of 
HPN) than the silicone 
group (0.03/patient 
year of HPN) 
Years of recruitment 
varied between the 2 
groups. Practice may 
have changed 
between 1991 and 
1998. 
More patients were in 
the silicone catheter 
group (N = 31) as well 
as catheters (N = 40) 
compared with the 
polyurethane group 
that had 11 patients 
with 13 CVADs. 
Measurement done 
per patient year of 
HPN. 
Gaggioti et al 12 
 
Retrospective HPN 
crossover 
Compared implanted 
ports and tunneled 
silicone CVADs 
6 adult HPN patients;  
All 6 previously had a 
silicone tunneled 
CVAD and changed to 
There were no data on 
the number of 
tunneled CVADs, and 3 
occlusions occurred in 
Authors did not state 
if the 1000 days were 
CVAD or HPN days. 
No definition for 
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an implanted port 1 patient occlusions. 
No statistics given in 
the paper. 
Small study group. 
      
CLABSI, central line–associated blood stream infection; CVAD, central venous access 
device; HPN, home parenteral nutrition; IV, intravenous; PICC, peripherally inserted central 
catheter; VAD, venous access device.  
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Table 8: Question #5: Should antimicrobial/ethanol locks be used for treating or preventing 
CVAD infections? 
Reference Study Design Study Aim(s) Population, 
Setting, N 
Results/Outcome Comments 
Davidson 
et al19  
Retrospective, 
cohort 
Rate of 
CLABSI 
before and 
after 
antibiotic or 
ethanol lock 
 
59 eligible 
patients 
51 patients 
instilled 
their CVADs 
with 
antibiotic 
lock 
8 patients 
instilled 
their CVADs 
with 
ethanol lock 
Total of 313 CLABSI; 
before the use of a 
locking solution, the 
CLABSI rate was 
10.97 + 25.92/1000 
CVAD days; following 
locking 1.09 + 
2.53/1000 CVAD days 
(P < .001) 
For patients who 
instilled with ethanol 
lock: CLABSI rate was 
4.18/1000 CVAD days 
before locking and 
0.47/1000 CVAD days 
after locking 
For patients who 
instilled antimicrobial 
lock CLABSI rate was 
12.03/1000 CVAD 
days and 1.19 after 
locking 
Pre-vancomycin 
locks: rate was 
11.59/1000 CVAD 
days, and post- 
vancomycin locks 
decreased to 
1.04/1000 CVAD days 
No statistical 
significance in 
the reduction 
of VAD 
infection rates 
when 
antimicrobial 
locking was 
used 
compared 
with ethanol 
locking. 
Decision as to 
which lock 
solution used 
was made 
depending 
upon clinical 
evaluation 
and was not 
controlled. 
Patients could 
have used 
both an 
antimicrobial 
and ethanol 
lock, thus 
being included 
in both 
groups. The 
type of lock 
reported and 
use in the 
analyses was 
the lock that 
the patient 
was using the 
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majority of 
the time.  
The 
appropriate 
antimicrobial 
lock solution 
was based 
upon previous 
CLABSI 
episodes and 
the general 
incidence, not 
on an 
organism 
obtained from 
a blood 
culture. 
No mention as 
to how often a 
patient was 
instilling the 
lock 
technique.  
Small sample 
sizes in both 
groups. 
Lawinski 
et al20  
Retrospective, 
cohort 
Compare 
antimicrobial 
(according to 
blood culture 
results) with 
95% ethanol 
lock therapy 
versus CVAD 
removal 
 
428 adult 
patients 
receiving 
HPN 
 
181 patients 
developed 352 
episodes of CLABSI 
48 patients treated 
with ethanol/ 
antimicrobial lock 
versus 133 treated 
with CVAD removal 
and replacement of a 
new catheter 
Median numbers to 
CVAD infection 
complication after 
treatment 1053 ± 748 
No statistical 
differences in 
the 2 groups. 
CLABSI not 
defined. 
Ethanol lock 
used for 4 
days followed 
by 
antimicrobial 
lock for 4 
days; HPN 
restarted after 
last 
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days in antimicrobial 
/ethanol group and 
952 ± 709 days in the 
CVAD 
removal/replacement 
group 
Average time of 
catheter use after a 
CLABSI to next 
episode of infection: 
436 + 436 days 
antimicrobial 
/ethanol group; 468 + 
411 days CVAD 
removal/replacement 
group 
Re-infection in 
tunneled CVADs after 
treatment for CLABSI: 
431 ± 437 days in 
antimicrobial 
/ethanol group; 565 + 
443 CVAD 
removal/replacement 
group 
antimicrobial 
lock and if 
asymptomatic 
and repeat 
blood culture 
negative, 
patient sent 
home. 
 
John et 
al18  
 
Retrospective, 
cohort 
Patients 
served as their 
own control 
Investigated 
the efficacy 
of ethanol 
lock 
installation (3 
mL of 70% 
ethanol 
followed by 
10 mL 
normal 
saline) in 
reducing the 
incidence of 
CLABSIs  
 
31 adult 
HPN 
patients 
273 CLABSI-related 
admissions pre-
ethanol lock and 47 
admissions post-
ethanol lock/1000 
CVAD days  
CLABSI hospital 
admits /1000 
catheter days was 
10.04 before and 
6.48 after ethanol (P 
= .005) 
Incidence of CLABSIs 
decreased from 3.53 
before to 1.65 after 
Small sample 
size. 
No reported 
side effects or 
complications 
from ethanol 
lock.  
Only patients 
with silicone 
catheters 
received 
ethanol lock. 
In the pre-
ethanol lock 
population, 16 
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ethanol lock/1000 
CVAD days (P = 
0.011) 
Number of 
CVAD/1000 CVAD 
days was 6.14 before 
and 3.72 after 
ethanol (P = .15) 
Number of CVADs 
removed for CLABSI 
decreased from 3.31 
to 1.93 before and 
after ethanol for lock, 
P = .058 
Adjusted data for 
only tunneled CVADs 
demonstrated a 
reduction in CLABSI 
readmissions from 
10.1 pre-ethanol lock 
to 2.9/1000 CVAD 
days post-ethanol 
lock (P < .001) 
patients had 
PICCs for at 
least some of 
the infusion 
days. 
Number of 
catheter days 
in prelock 
group was 
27,210 and 
7201 in 
tunneled 
group with 
ethanol lock. 
Ethanol lock 
started on 
existing 
CVADs in 
which the 
presence of a 
biofilm could 
affect results. 
 
CLABSI, central line–associated blood stream infection; CVAD, central venous access 
device; HPN, home parenteral nutrition; IV, intravenous; VAD, venous access device. 
 
